article
Counterfeit drugs: a global problem
24 March 2016 | By Victoria White, European Pharmaceutical Review
We’ve created an infographic on counterfeit drugs, highlighting some of the actions taken to counter this global problem...
List view / Grid view
Pfizer
news
EMA accepts Pfizer’s MAA for Xeljanz in rheumatoid arthritis
24 March 2016 | By Victoria White
Xeljanz is the only oral Janus kinase (JAK) inhibitor approved in more than 45 countries around the world for the treatment of moderate to severe RA...
news
Pfizer announces results from studies of tofacitinib in ulcerative colitis
21 March 2016 | By Victoria White
Results from OCTAVE Induction 1 and 2, evaluating the efficacy and safety of oral tofacitinib in inducing remission in ulcerative colitis, were presented at ECCO...
news
FDA approves sNDA for Xalkori in ROS1-positive NSCLC
14 March 2016 | By Victoria White
The approval is based on a Phase I study that included 50 patients with ROS1-positive metastatic NSCLC treated with 250 mg of Pfizer's Xalkori (crizotinib) orally twice daily...
news
FDA approves expanded indication for Pfizer’s Ibrance
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
news
Sandoz acquires rights to biosimilar infliximab in the EEA
12 February 2016 | By Victoria White
Infliximab is a tumour necrosis factor alpha (TNF-alpha) inhibitor used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis...
news
Executive leadership team named for the combined Allergan Pfizer business
8 February 2016 | By Victoria White
The close of the transaction to combine Pfizer and Allergan is expected in the second half of 2016, and is subject to certain conditions...
news
BMS, Pfizer and Portola team up to bring andexanet alfa to Japan
1 February 2016 | By Victoria White
Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)...
article
European Pharmaceutical Review’s top 10 stories from 2015
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
news
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
news
Trial to investigate avelumab and entinostat in ovarian cancer
4 January 2016 | By Victoria White
Avelumab is an investigational fully human anti-PD-L1 IgG1 monoclonal antibody and entinostat is an investigational oral small molecule that targets immune regulatory cells...
news
Merck KGaA and Pfizer advance avelumab clinical development programme
22 December 2015 | By
Merck KGaA and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab in patients with ovarian cancer...
news
BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
news
COMP issues positive opinion for ODD for avelumab in MCC
1 December 2015 | By Victoria White
An official decision on the Ophran Drug Designation is expected from the European Commission in December...
news
EC approves label update for Pfizer’s Xalkori in NSCLC
26 November 2015 | By Victoria White
The EC has approved a label update to expand the use of Xalkori (crizotinib) to first-line treatment of adults with ALK-positive NSCLC...
